ScoreWhy is InventionMed SA ?
1
Weak Long Term Fundamental Strength with an average Return on Capital Employed (ROCE) of 0%
- Poor long term growth as Net Sales has grown by an annual rate of 36.45% and Operating profit at 22.97% over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -1.42
2
The company has declared Positive results for the last 5 consecutive quarters
- PRE-TAX PROFIT(Q) At PLN 0.24 MM has Grown at 2,139.41%
- NET PROFIT(Q) At PLN 0.24 MM has Grown at 2,139.41%
- ROCE(HY) Highest at 68.11%
3
With ROE of 4.15%, it has a expensive valuation with a 0.00 Price to Book Value
- Over the past year, while the stock has generated a return of -34.14%, its profits have risen by 100.9%
4
Consistent Underperformance against the benchmark over the last 3 years
- Along with generating -34.14% returns in the last 1 year, the stock has also underperformed Poland WIG in each of the last 3 annual periods
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to InventionMed SA should be less than 10%
- Overall Portfolio exposure to Software Products should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Software Products)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is InventionMed SA for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
InventionMed SA
-100.0%
-1.18
44.75%
Poland WIG
37.09%
2.22
16.73%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
36.45%
EBIT Growth (5y)
22.97%
EBIT to Interest (avg)
-1.10
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
0.34
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
3.77%
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
Industry P/E
Price to Book Value
NA
EV to EBIT
3.33
EV to EBITDA
1.94
EV to Capital Employed
0.77
EV to Sales
0.89
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
18.85%
ROE (Latest)
4.15%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
Bullish
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
Mildly Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend17What is working for the Company
PRE-TAX PROFIT(Q)
At PLN 0.24 MM has Grown at 2,139.41%
NET PROFIT(Q)
At PLN 0.24 MM has Grown at 2,139.41%
ROCE(HY)
Highest at 68.11%
RAW MATERIAL COST(Y)
Fallen by -922.41% (YoY
NET SALES(9M)
Higher at PLN 2.51 MM
0What is not working for the Company
NO KEY NEGATIVE TRIGGERS
Here's what is working for InventionMed SA
Pre-Tax Profit
At PLN 0.24 MM has Grown at 2,139.41%
over average net sales of the previous four periods of PLN 0.01 MMMOJO Watch
Near term Pre-Tax Profit trend is very positive
Pre-Tax Profit (PLN MM)
Net Profit
At PLN 0.24 MM has Grown at 2,139.41%
over average net sales of the previous four periods of PLN 0.01 MMMOJO Watch
Near term Net Profit trend is very positive
Net Profit (PLN MM)
Net Sales
Higher at PLN 2.51 MM
than preceding 12 month period ended Jun 2026MOJO Watch
In the nine month period the company has already crossed sales of the previous twelve months
Net Sales (PLN MM)
Raw Material Cost
Fallen by -922.41% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
